 "Torrent Pharma acquires four therapy segment brands from Dr Reddy's")
Ahmedabad-based Torrent Pharmaceuticals said on Thursday it has entered into an agreement to acquire four brands from Dr Reddy's Laboratories Ltd. (DRL). 'Styptovit-E', 'Finast', 'Finast-T', and 'Dynapress' will strengthen Torrent’s presence in the therapy segment.
Styptovit-E, a gynaecology product, has an estimated market size of roughly Rs 500 crore, according to data from AIOCD, a pharmaceutical market research company.
'Finast', 'Finast-T', and 'Dynapress' are used in the treatment of Benign Prostatic Hyperplasia (BPH) and they will aid Torrent's presence in the urology therapy.
The terms of the definitive agreement mandate that Torrent Pharma will take over the manufacturing, marketing, and distribution of these brands in India.
The two sides did not reveal the amount paid for the acquisition.
The integration and transition of the brands is expected to be completed by June 2022.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%